

Biotech Daily



Tuesday February 8, 2011

Daily news on ASX-listed biotechnology companies

AUSBIOTECH BRIEFING: STOP THE GENE PATENT BILL

AUSBIOTECH

Ausbiotech says a proposed Bill in the Australian Senate “is threatening scientific research sustained by patents– on all biological materials”. Inviting the members to a February 11, 2011 briefing on the Patent Amendment (Human Genes and Biological Materials) Bill 2010, Ausbiotech says the industry needs to “find out why you should be concerned and what you can do to ensure the Bill is rejected”. “If this Bill becomes law, Australians will be denied the improved access to health care that stimulated the debate in the first place,” Ausbiotech said. The industry organization said that experts in patent law, medical research and the biotechnology industry would present “the side of the debate that is not being given enough attention and demonstrate why the Bill is flawed and does not serve the interests of patients, researchers or industry”. Ausbiotech chief executive officer Dr Anna Lavelle will provide an industry perspective and overview entitled ‘Ausbiotech’s campaign to reject the Bill’ and a Griffith Hack principal Amanda Stark will discuss the legal perspective in a talk entitled ‘Gene patents -what is all the fuss about?’ Walter and Eliza Hall Institute for Medical Research head of business development Dr Julian Clark will discuss the topic ‘Do patents hinder research? A practical perspective.’ The member briefing will be held at the Walter and Eliza Hall Institute, Level 7, 1G Royal Parade, Parkville, Victoria on February 11, 2011 from 3.30pm until 6pm. For registration contact Ausbiotech’s Lorraine Chiroiu by email: lchiroiu@ausbiotech.org.

Biotech Daily can be contacted at: PO Box 5000, Carlton, Victoria, Australia, 3053
email: editor@biotechdaily.com.au www.biotechdaily.com.au